Home > Insider Trading > Filing (0001477932-25-002818)

Filing Details

Accession Number:: 0001477932-25-002818
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-04-17 16:06:40
Reporting Period:: 2025-03-06

Filing Date:: 2025-04-17
Accepted Time:: 2025-04-17 16:06:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
924515	Guided Therapeutics Inc	GTHP	Electromedical & Electrotherapeutic Apparatus (3845)	582029543

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1348439	E John Imhoff	5853 Peachtree Corners East Suite B Peachtree Corners GA 30092		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Preferred Series D Stock	Disposition	2025-03-06	300	$0.00	0	No	4	J	Direct
Common Stock	Acquisiton	2025-03-06	900,000	$0.00	9,662,756	No	4	J	Direct
Preferred Series C2 Stock	Disposition	2025-03-06	2,401	$0.00	0	No	4	J	Direct
Common Stock	Acquisiton	2025-03-06	4,801,500	$0.50	14,464,256	No	4	J	Direct
Preferred Series C Stock	Acquisiton	2025-03-07	286	$0.00	286	No	4	P	Direct
Preferred Series C Stock	Disposition	2025-03-11	286	$0.00	0	No	4	J	Direct
Common Stock	Acquisiton	2025-03-11	2,258,690	$0.13	16,722,946	No	4	J	Direct
Common Stock	Acquisiton	2025-03-18	1,000,000	$0.10	17,722,946	No	4	P	Direct
Common Stock	Acquisiton	2025-03-18	263,069	$0.10	17,986,015	No	4	P	Direct
Common Stock	Acquisiton	2025-04-10	6,365	$0.00	17,992,380	No	4	J	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	J	Direct
No	4	J	Direct
No	4	J	Direct
No	4	J	Direct
No	4	P	Direct
No	4	J	Direct
No	4	J	Direct
No	4	P	Direct
No	4	P	Direct
No	4	J	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants	Acquisiton	2025-03-18	1,000,000	$0.00	1,000,000	$0.13
Common Stock	Warrants	Acquisiton	2025-03-18	263,069	$0.00	263,069	$0.13

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,000,000	2025-03-18	2029-03-17	No	4	P	Direct
1,263,069	2025-03-18	2029-03-17	No	4	P	Direct

Footnotes

On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price.
On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares.
On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares.
On March 18, 2025, the Company entered into a Securities Purchase Agreement (the "March Purchase Agreement") with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $100,000, 1,000,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 1,000,000 shares of common stock (the "March Warrants"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share.
In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above.
These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943.